The full investigation launched by the European Medicines Agency (EMA), in close cooperation with law enforcement and other relevant entities, demonstrated that data has been breached. An initial review revealed that a limited number of documents belonging to third parties were unlawfully accessed. The concerned companies are being informed.

The Agency remains fully functional and its timelines related to the evaluation and approval of COVID-19 vaccines and treatments are not affected.

EMA will continue to provide information in due course, to the extent possible, given its duty towards the ongoing investigations.

Share this page